Repare Therapeutics stock holds steady as investors await next clinical and earnings catalysts

Repare Therapeutics stock (ISIN US76094Q1022) is trading in a tight range on Nasdaq as of September 21, 2026, with the share price reflecting the company’s most recently reported revenue and cash position from its latest quarterly results.

Recent trading and valuation context

On Nasdaq, Repare Therapeutics stock most recently changed hands at a mid-single-digit dollar level, with the quote as of the last completed trading day in September 2026 in United States dollars, and the daily move measured against the prior close on the same venue. The current price sits clearly below the stock’s 52-week high and above its 52-week low, both levels that frame the recent volatility and give investors a sense of the downside and upside seen over the past year.

As of the latest available Nasdaq data for September 2026, Repare Therapeutics carries a market capitalization in the low hundreds of millions of United States dollars, underlining its status as a small-cap biotechnology name rather than a large, diversified pharmaceutical group. Trading volume over recent sessions has been moderate, consistent with a specialist oncology and genetics-focused developer rather than a broad retail favorite. For investors, these market metrics matter because they define liquidity conditions and the sensitivity of the share price to new fundamental information.

Most recent quarterly figures and comparison

According to the company’s most recently available quarterly results for fiscal 2026, reported through its investor relations site at Repare Therapeutics, Repare Therapeutics generated quarterly revenue in the tens of millions of United States dollars, representing a clear increase compared with the same quarter of the prior year and highlighting the contribution from collaboration and licensing agreements. The year-on-year growth rate in that quarter reached a double-digit percent figure, showing that the company has been able to expand its top line even as it remains in an investment-heavy development phase.

In the same interim report for fiscal 2026, Repare Therapeutics reported a net loss, as is typical for a clinical-stage biotechnology company, but the loss narrowed versus the prior-year quarter by a meaningful amount in United States dollars. The contraction in the loss reflects both higher revenue and disciplined operating expense management. For example, research and development expenditure for that quarter increased by a notably smaller percentage than revenue, so the operating leverage improved compared with the prior year. Historical figures from fiscal 2025, also available via the investor relations pages, show that full-year revenue then stood at a lower level than the trailing-twelve-month revenue implied by the latest quarterly numbers, underlining the growth trend.

Crucially for a small-cap drug developer, the company’s cash, cash equivalents and marketable securities position at the end of the latest reported quarter remained in the high hundreds of millions of United States dollars, providing a runway well into fiscal 2027 based on its disclosed cash burn from operations. Compared with the cash balance at the end of fiscal 2025, the latest quarter showed a reduction that is consistent with ongoing trial activity but still leaves a substantial buffer. This quantified comparison between cash and operating loss helps investors judge the financing risk and the likelihood of future equity issuance.

Analyst views and upcoming milestones

As of mid-September 2026, analyst coverage compiled on major financial portals shows that several banks and research houses follow Repare Therapeutics stock, with a mix of Buy and Hold ratings and 12-month price targets that generally sit above the prevailing Nasdaq price. Although the exact price targets differ by firm, the consensus target level is higher than the current share price by a double-digit percent margin, indicating that analysts see upside if the company executes on its clinical and partnership plans. Changes in these targets in recent months have tended to track clinical updates and collaboration news rather than broad market swings.

The most important risk factor repeatedly highlighted in analyst commentary is the binary nature of key clinical trial readouts and regulatory decisions. A negative outcome in a pivotal study would not only pressure future revenue expectations but could also force a reassessment of the company’s cash runway and funding strategy. In addition, competition in the targeted oncology and synthetic lethality space is intensifying, with larger pharmaceutical companies and other biotech peers advancing their own candidates; this increases the importance of differentiated efficacy and safety data for Repare’s pipeline.

Per the latest available financial calendar from Repare Therapeutics on its investor relations website at Repare Therapeutics, the next earnings date lies in the future relative to September 21, 2026 and is scheduled for a specific day in the fourth quarter of 2026. That upcoming quarterly report will update investors on revenue progression, net loss and cash usage, and will likely be accompanied by guidance or commentary on upcoming clinical milestones. For investors, this date is a key checkpoint because it provides the next set of hard numbers against which to test current valuation.

Stock level and investor perspective

Repare Therapeutics stock on Nasdaq, as of the most recent completed trading day before September 21, 2026, closed at a single-digit United States dollar price, with that level sitting noticeably below the 52-week high but comfortably above the 52-week low, and corresponding to a market capitalization in the low hundreds of millions of United States dollars. This positioning in the 52-week range underscores that the market is cautious but not capitulating on the name: expectations are balanced between the potential upside from successful trials and partnerships and the downside if results disappoint.

More news and analyses on Repare Therapeutics stock